{"id":342886,"date":"2026-11-10T11:21:15","date_gmt":"2026-11-10T05:51:15","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=342886"},"modified":"2026-11-10T11:21:15","modified_gmt":"2026-11-10T05:51:15","slug":"divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/","title":{"rendered":"Divi&#8217;s Labs Share Price: 49.0% CAGR in 3 Years as the API Major Outpaces Gland Pharma and Sun Pharma"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#Divis_Labs_Share_Price_490_CAGR_in_3_Years_as_the_API_Major_Outpaces_Gland_Pharma_and_Sun_Pharma\" title=\"Divi&#8217;s Labs Share Price: 49.0% CAGR in 3 Years as the API Major Outpaces Gland Pharma and Sun Pharma\">Divi&#8217;s Labs Share Price: 49.0% CAGR in 3 Years as the API Major Outpaces Gland Pharma and Sun Pharma<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#How_Much_Has_the_Divis_Labs_Share_Price_Returned_in_3_Years\" title=\"How Much Has the Divi&#8217;s Labs Share Price Returned in 3 Years?\">How Much Has the Divi&#8217;s Labs Share Price Returned in 3 Years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#Divis_Labs_vs_Laurus_Labs_Gland_Pharma_and_Sun_Pharmaceutical_Industries_3-Year_CAGR_Compared\" title=\"Divi&#8217;s Labs vs Laurus Labs, Gland Pharma and Sun Pharmaceutical Industries: 3-Year CAGR Compared\">Divi&#8217;s Labs vs Laurus Labs, Gland Pharma and Sun Pharmaceutical Industries: 3-Year CAGR Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#Valuation_and_Quality_Compared\" title=\"Valuation and Quality Compared\">Valuation and Quality Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#What_Is_Driving_the_Divis_Labs_Stock\" title=\"What Is Driving the Divi&#8217;s Labs Stock?\">What Is Driving the Divi&#8217;s Labs Stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#How_the_Established_Players_Stack_Up\" title=\"How the Established Players Stack Up\">How the Established Players Stack Up<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#What_Should_Investors_Track_Next\" title=\"What Should Investors Track Next?\">What Should Investors Track Next?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#How_to_Compare_Pharma_Stocks_Yourself\" title=\"How to Compare Pharma Stocks Yourself\">How to Compare Pharma Stocks Yourself<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#A_Large_Ingredient_Maker_With_a_Debt_Free_Balance_Sheet\" title=\"A Large Ingredient Maker With a Debt Free Balance Sheet\">A Large Ingredient Maker With a Debt Free Balance Sheet<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#What_is_the_Divis_Labs_share_price_today\" title=\"What is the Divi&#8217;s Labs share price today?\">What is the Divi&#8217;s Labs share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#What_is_the_3-year_CAGR_of_the_Divis_Labs_stock\" title=\"What is the 3-year CAGR of the Divi&#8217;s Labs stock?\">What is the 3-year CAGR of the Divi&#8217;s Labs stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#Is_Divis_Labs_better_than_Laurus_Labs\" title=\"Is Divis Labs better than Laurus Labs?\">Is Divis Labs better than Laurus Labs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#What_does_Divis_Laboratories_do\" title=\"What does Divi&#8217;s Laboratories do?\">What does Divi&#8217;s Laboratories do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#Is_the_Divis_Labs_stock_debt_free\" title=\"Is the Divi&#8217;s Labs stock debt free?\">Is the Divi&#8217;s Labs stock debt free?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#Is_Divis_Labs_expensive_compared_with_the_industry\" title=\"Is Divi&#8217;s Labs expensive compared with the industry?\">Is Divi&#8217;s Labs expensive compared with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#Which_pharma_stock_gave_the_highest_return_in_3_years\" title=\"Which pharma stock gave the highest return in 3 years?\">Which pharma stock gave the highest return in 3 years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/divis-labs-share-price-3-year-cagr-vs-pharma-peers-laurus-gland-sun\/#How_do_I_calculate_CAGR_for_a_stock\" title=\"How do I calculate CAGR for a stock?\">How do I calculate CAGR for a stock?<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h1><span class=\"ez-toc-section\" id=\"Divis_Labs_Share_Price_490_CAGR_in_3_Years_as_the_API_Major_Outpaces_Gland_Pharma_and_Sun_Pharma\"><\/span><strong>Divi&#8217;s Labs Share Price: 49.0% CAGR in 3 Years as the API Major Outpaces Gland Pharma and Sun Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h1>\n<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Divi&#8217;s Labs previous close Rs 11,565.50. 3-year CAGR 49.0%. Up 3.3x since 9 Nov 2023. ROE 15.32%. Market cap Rs 3,07,147 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Divi&#8217;s Labs share price<\/strong> closed at Rs 11,565.50 on 9 November 2026, a compounded annual return of 49.0% over three years. That compares with Laurus Labs at 87.9%, Gland Pharma at 27.0% and Sun Pharmaceutical Industries at 17.4%. The company has a market cap of Rs 3,07,147 crore and a P\/E of 91.33 against an industry P\/E of 40.13.<\/p>\n<\/p><\/div>\n<p>The <strong>Divi&#8217;s Labs share price<\/strong> has delivered one of the strongest three-year runs among large Indian pharma names. Divi&#8217;s Laboratories, the Hyderabad-based maker of generic active pharmaceutical ingredients and custom synthesis products, has more than tripled investor money while remaining a very large company by market cap.<\/p>\n<p>We compare that record with Laurus Labs, Gland Pharma and Sun Pharmaceutical Industries. The article calculates three-year CAGR for all four and sets the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=divis-labs-share-price\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Much_Has_the_Divis_Labs_Share_Price_Returned_in_3_Years\"><\/span><strong>How Much Has the Divi&#8217;s Labs Share Price Returned in 3 Years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Divi&#8217;s Labs stock closed at Rs 3,498.50 on 9 November 2023 and at Rs 11,565.50 on 9 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 3.31 lakh, which is a CAGR of 49.0%. This is a price return and leaves out dividends.<\/p>\n<p>CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Divi&#8217;s Labs can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.<\/p>\n<p>The <strong>Divi&#8217;s Labs share price<\/strong> has also benefited from the global shift of ingredient supply chains towards reliable Indian manufacturers, which has supported the order books of large API makers.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Divis_Labs_vs_Laurus_Labs_Gland_Pharma_and_Sun_Pharmaceutical_Industries_3-Year_CAGR_Compared\"><\/span><strong>Divi&#8217;s Labs vs Laurus Labs, Gland Pharma and Sun Pharmaceutical Industries: 3-Year CAGR Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table ranks the companies by three-year CAGR. Prices on 9 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 9 November 2026.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Close on 9 Nov 2023<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Previous close (9 Nov 2026)<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Price multiple<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">3-year CAGR<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Laurus Labs<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 369.70<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 2,454.00<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">6.6x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">87.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Divi&#8217;s Laboratories<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 3,498.50<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 11,565.50<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">3.3x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">49.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Gland Pharma<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,612.65<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 3,302.40<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">2.0x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">27.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Sun Pharmaceutical Industries<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,176.20<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,904.50<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.6x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">17.4%<\/td>\n<\/tr>\n<\/table>\n<p>The Divi&#8217;s Labs stock ranks second of the four at 49.0%. It sits ahead of Gland Pharma (27.0%) and Sun Pharmaceutical Industries (17.4%). The company ahead is Laurus Labs (87.9%). Laurus Labs leads the group on percentage return, with Divi&#8217;s in second place, followed by Gland Pharma and Sun Pharma. Divi&#8217;s is far bigger than Laurus and Gland by market cap, so its return came on a larger base of capital.<\/p>\n<p>Look at the <strong>Divi&#8217;s Labs share price<\/strong> alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_and_Quality_Compared\"><\/span><strong>Valuation and Quality Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Market cap<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Debt to equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharmaceutical Industries<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 4,57,073 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">41.60<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">13.79%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.04<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/divislab\/divi%27s-laboratories-ltd-share-price-today\">Divi&#8217;s Laboratories<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 3,07,147 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">91.33<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">15.32%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/lauruslabs\/laurus-labs-ltd-share-price-today\">Laurus Labs<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,32,376 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">99.35<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">22.11%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.43<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Gland Pharma<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 54,476 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">44.08<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">11.57%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.02<\/td>\n<\/tr>\n<\/table>\n<p>By market cap, Sun Pharmaceutical Industries is the largest of the group at Rs 4,57,073 crore, while the Divi&#8217;s Labs stock stands at Rs 3,07,147 crore, about 67% of that size. On earnings, Divi&#8217;s Labs shares trade at a P\/E of 91.33 against an industry P\/E of 40.13, a premium of about 128%, which signals that the market expects faster earnings growth. Peer multiples are Laurus Labs at 99.35, Gland Pharma at 44.08 and Sun Pharmaceutical Industries at 41.60.<\/p>\n<p>Return on equity is 15.32% for the Divi&#8217;s Labs stock, which ranks second among the four, and debt to equity stands at 0.00. Trailing EPS is Rs 126.68. Pharma companies with strong ingredient franchises often trade at premium multiples, so P\/E should be read together with return on equity and the pace of earnings growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Driving_the_Divis_Labs_Stock\"><\/span><strong>What Is Driving the Divi&#8217;s Labs Stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Divi&#8217;s Laboratories makes generic active pharmaceutical ingredients, custom synthesis products for global innovators and nutraceutical ingredients. Its customers include large pharma companies around the world.<\/p>\n<p>Custom synthesis work often runs over long periods, because innovators prefer to stay with a supplier that has proven quality and delivery. That can give the business steady repeat demand.<\/p>\n<p>Followers of the <strong>Divi&#8217;s Labs share price<\/strong> usually track custom synthesis orders, capacity expansion, margins and the product mix between generics and contract work.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_the_Established_Players_Stack_Up\"><\/span><strong>How the Established Players Stack Up<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Laurus Labs is a Hyderabad-based maker of ingredients and formulations that has been widening into contract development and manufacturing. It compounded at 87.9% a year, on a market cap of Rs 1,32,376 crore and an ROE of 22.11%.<\/p>\n<p>Gland Pharma is a Hyderabad-based injectables specialist that supplies regulated markets. It compounded at 27.0% a year, on a market cap of Rs 54,476 crore and an ROE of 11.57%.<\/p>\n<p>Sun Pharmaceutical Industries is one of the largest pharma companies in India, with a broad generics and specialty portfolio. It compounded at 17.4% a year, on a market cap of Rs 4,57,073 crore and an ROE of 13.79%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Track_Next\"><\/span><strong>What Should Investors Track Next?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Three things are worth watching on the <strong>Divi&#8217;s Labs share price<\/strong>. First, the order flow for custom synthesis and new molecules. Second, margins as capacity is added. Third, the progress of new capacity and its contribution to revenue.<\/p>\n<p>At a P\/E of 91, expectations are high. Earnings in this space can be uneven, so size any position with that in mind.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live fundamentals of pharma stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Compare_Pharma_Stocks_Yourself\"><\/span><strong>How to Compare Pharma Stocks Yourself<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>You can repeat this exercise for any pair of stocks, including the Divi&#8217;s Labs stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P\/E against the industry P\/E, ROE and debt to equity. Benchmark the result against the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> as well, so you know whether the stock beat the broader market.<\/p>\n<p>A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the <strong>Divi&#8217;s Labs share price<\/strong>, the same four checks give a more complete picture than price alone.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the <strong>Divi&#8217;s Labs share price<\/strong> and compare pharma stocks live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"A_Large_Ingredient_Maker_With_a_Debt_Free_Balance_Sheet\"><\/span><strong>A Large Ingredient Maker With a Debt Free Balance Sheet<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Divi&#8217;s Labs share price<\/strong> compounded at 49.0% a year over three years, ahead of Gland Pharma at 27.0% and Sun Pharma at 17.4%, and behind Laurus Labs at 87.9%. It is debt free, with a debt to equity of 0.00.<\/p>\n<p>Laurus brings a faster record from a smaller base, Gland Pharma offers an injectables focus at a lower multiple, and Sun Pharma brings scale and diversification. The choice depends on how much valuation risk you are comfortable with.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Divis_Labs_share_price_today\"><\/span><strong>What is the Divi&#8217;s Labs share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Laboratories closed at Rs 11,565.50 on 9 November 2026, according to NSE data. It has a market cap of Rs 3,07,147 crore and a P\/E of 91.33. Check live quotes before acting, as prices change every trading day.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_3-year_CAGR_of_the_Divis_Labs_stock\"><\/span><strong>What is the 3-year CAGR of the Divi&#8217;s Labs stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Laboratories delivered a price CAGR of 49.0% over three years, moving from Rs 3,498.50 on 9 November 2023 to Rs 11,565.50 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Divis_Labs_better_than_Laurus_Labs\"><\/span><strong>Is Divis Labs better than Laurus Labs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Laurus Labs stock delivered a higher three-year CAGR at 87.9% than Divi&#8217;s at 49.0%. Divi&#8217;s is far larger by market cap at Rs 3,07,147 crore, while Laurus has the higher ROE at 22.11% against 15.32%. Both trade at premium multiples, so the better choice depends on your view of growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Divis_Laboratories_do\"><\/span><strong>What does Divi&#8217;s Laboratories do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Laboratories is a Hyderabad-based pharmaceutical company that makes generic active pharmaceutical ingredients, custom synthesis products and nutraceutical ingredients for global customers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_Divis_Labs_stock_debt_free\"><\/span><strong>Is the Divi&#8217;s Labs stock debt free?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The debt to equity ratio of the Divi&#8217;s Labs stock is 0.00 and its return on equity is 15.32%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Divis_Labs_expensive_compared_with_the_industry\"><\/span><strong>Is Divi&#8217;s Labs expensive compared with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Labs trades at a P\/E of 91.33 against an industry P\/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_stock_gave_the_highest_return_in_3_years\"><\/span><strong>Which pharma stock gave the highest return in 3 years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among the companies compared here, Laurus Labs delivered the highest three-year CAGR at 87.9%, followed by Divi&#8217;s Laboratories at 49.0%. Past returns do not guarantee future performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_do_I_calculate_CAGR_for_a_stock\"><\/span><strong>How do I calculate CAGR for a stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Divi's Labs share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divi's Laboratories closed at Rs 11,565.50 on 9 November 2026, according to NSE data. It has a market cap of Rs 3,07,147 crore and a P\/E of 91.33. Check live quotes before acting, as prices change every trading day.\"}},{\"@type\":\"Question\",\"name\":\"What is the 3-year CAGR of the Divi's Labs stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divi's Laboratories delivered a price CAGR of 49.0% over three years, moving from Rs 3,498.50 on 9 November 2023 to Rs 11,565.50 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Is Divis Labs better than Laurus Labs?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Laurus Labs stock delivered a higher three-year CAGR at 87.9% than Divi's at 49.0%. Divi's is far larger by market cap at Rs 3,07,147 crore, while Laurus has the higher ROE at 22.11% against 15.32%. Both trade at premium multiples, so the better choice depends on your view of growth.\"}},{\"@type\":\"Question\",\"name\":\"What does Divi's Laboratories do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divi's Laboratories is a Hyderabad-based pharmaceutical company that makes generic active pharmaceutical ingredients, custom synthesis products and nutraceutical ingredients for global customers.\"}},{\"@type\":\"Question\",\"name\":\"Is the Divi's Labs stock debt free?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The debt to equity ratio of the Divi's Labs stock is 0.00 and its return on equity is 15.32%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.\"}},{\"@type\":\"Question\",\"name\":\"Is Divi's Labs expensive compared with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divi's Labs trades at a P\/E of 91.33 against an industry P\/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma stock gave the highest return in 3 years?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among the companies compared here, Laurus Labs delivered the highest three-year CAGR at 87.9%, followed by Divi's Laboratories at 49.0%. Past returns do not guarantee future performance.\"}},{\"@type\":\"Question\",\"name\":\"How do I calculate CAGR for a stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Divi&#8217;s Labs share price compounded at 49.0% a year over 3 years. See how Divi&#8217;s compares with Laurus Labs, Gland Pharma and Sun Pharma on returns and ROE.<\/p>\n","protected":false},"author":38,"featured_media":342885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[21455,21335,21524,21525],"class_list":["post-342886","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-api-stocks-3-year-return","tag-divis-laboratories-share-price","tag-divis-labs-share-price","tag-divis-labs-vs-laurus-labs"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["342885"],"rank_math_title":["Divi's Labs Share Price: 49.0% CAGR vs Laurus, Sun"],"rank_math_description":["Divi's Labs share price compounded at 49.0% a year over 3 years. See how Divi's compares with Laurus Labs, Gland Pharma and Sun Pharma on returns and ROE."],"rank_math_focus_keyword":["Divi's Labs share price | Density Target: 1.2-1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/divi-s-labs-share-price-49-0-cagr-in-3-years-as-the-api-major-outpaces-gland.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/342886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=342886"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/342886\/revisions"}],"predecessor-version":[{"id":342887,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/342886\/revisions\/342887"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/342885"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=342886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=342886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=342886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}